Purple Biotech Partners with Converge Bio to Accelerate AI-Driven Tri-Specific Antibody Development
Key Insights
Purple Biotech (search) announced a collaboration with Converge Bio (search) to leverage generative AI for designing and optimizing next-generation tri-specific antibodies targeting solid tumors (search).
The partnership aims to significantly reduce discovery timelines while improving candidate quality and developability profiles for Purple Biotech (search)'s CAPTN-3 (search) platform.
Converge Bio (search)'s AI platform integrates large-scale biological data with predictive modeling to tackle complex antibody engineering challenges from binding kinetics to manufacturability.
Purple Biotech (search) Ltd. (NASDAQ/TASE: PPBT) announced a strategic collaboration with Converge Bio (search) to accelerate development of its next-generation tri-specific antibody platform using advanced generative artificial intelligence capabilities. The partnership leverages Converge Bio's proprietary AI platform to design and optimize novel tri-specific antibodies for oncology applications, with the goal of significantly reducing discovery timelines while enhancing molecule quality for drug candidates targeting solid tumors (search).
AI-Powered Antibody Engineering
The collaboration will utilize Converge Bio (search)'s proprietary AI platform, which integrates large-scale biological data with predictive modeling and iterative learning, to design and optimize antibody candidates. The CAPTN-3 (search) platform has demonstrated the ability to generate novel, high-affinity antibodies and optimize protein sequences for improved manufacturability and developability. Purple Biotech (search) will apply these AI-driven insights to develop novel T cell engagers, with the goal of creating drug candidates that combine optimal functional properties with favorable physicochemical characteristics.
"We are excited to expand our relationship with Converge Bio (search), whose AI platform has already contributed valuable insights to our CAPTN-3 (search) platform," said Gil Efron, Chief Executive Officer of Purple Biotech (search). "This collaboration is a natural extension of Purple Biotech's strategy to lead innovation in multi-specific antibody therapies. By integrating Converge Bio's generative AI with our deep expertise in tumor immunology and conditional activation, we aim to develop next-generation therapeutics that can address some of oncology's most challenging targets with improved speed and precision."
Building on CAPTN-3 Technology
This next-generation platform is designed to complement and build upon insights gained from Purple Biotech (search)'s existing CAPTN-3 (search) technology, which generates masked tri-specific antibodies that engage both T cells and NK cells. CAPTN-3's proprietary capping technology confines immune activation to the tumor microenvironment by masking the CD3 (search)-binding arm in circulation and activating it only at the tumor site, significantly expanding the therapeutic window versus unmasked T-cell engagers.
The platform's lead candidates include IM1240 (targeting 5T4 (search)) and IM1305 (search) (targeting TROP2 (search)), both currently in preclinical development. IM1240 is advancing toward the clinic as Purple Biotech (search)'s lead candidate.
Validated AI Partnership
Converge Bio (search) brings significant experience to the collaboration, having completed over 40 programs with pharmaceutical and biotech companies. The company was founded in 2024 and employs a 40-person team with deep expertise in machine learning, computational biology, and drug development, with approximately half holding advanced degrees in related fields.
"Purple Biotech (search)'s CAPTN-3 (search) platform represents an innovative approach to immuno-oncology, and we're thrilled to deepen our collaboration with Purple Biotech as they advance their next-generation tri-specific antibody capabilities," said Dov Gertz, CEO and co-founder of Converge Bio (search). "Our AI platform is purpose-built to tackle the complex challenges of antibody engineering - from achieving optimal binding kinetics to ensuring manufacturability at scale. This collaboration exemplifies how AI can accelerate the development of sophisticated biologics that have the potential to make a meaningful difference for cancer patients."
Strategic Expansion
The collaboration represents a strategic expansion that broadens Purple Biotech (search)'s platform capabilities to address additional high-value oncology targets and resistance mechanisms. By leveraging AI to accelerate antibody design and optimization, Purple Biotech aims to expand its pipeline with additional high-quality candidates while reducing development timelines.
Purple Biotech (search)'s broader pipeline also includes CM24, a CEACAM1 (search)-blocking antibody that demonstrated improved outcomes across all efficacy endpoints in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (search), and NT219, a dual IRS1/2 (search) and STAT3 (search) inhibitor in a Phase 2 study for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (search). Further development of these clinical-stage assets is pending partnering or investment.
The collaboration positions Purple Biotech (search) at the intersection of cutting-edge AI-driven drug discovery and innovative immuno-oncology, potentially accelerating the company's path to generate differentiated, high-quality therapeutic candidates with an improved probability of clinical success.